Evidence map›Paper›PMID 37766218›Full record

ArticleViruses2023

Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance.

Johannes C Botha, Matthew Byott, Moira J Spyer, Paul R Grant, Kathleen Gärtner, Wilson X Chen, James Burton, Alasdair Bamford, Laura J Waters, Carlo Giaquinto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Johannes C BothaGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.ORCID 0000-0002-7635-7810
Matthew ByottGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Moira J SpyerGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Paul R GrantHealth Services Laboratories, London WC1H 9AX, UK.
Kathleen GärtnerGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Wilson X ChenViiV Healthcare, Durham, NC 27709, USA.
James BurtonGreat Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.
Alasdair BamfordGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Laura J WatersCentral and North West London NHS Foundation Trust, Mortimer Market, London WC1E 6JB, UK.
Carlo GiaquintoDepartment of Women and Child Health, University of Padova, 35122 Padova, Italy.
Anna TurkovaGreat Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK.ORCID 0000-0002-7008-4145
Cindy L VavroViiV Healthcare, Durham, NC 27709, USA.
Eleni NastouliGreat Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.

Funding

Medical Research Council MC_UU_00004/03
6 · The paper itself

Abstract

Modern HIV-1 treatment effectively suppresses viral amplification in people living with HIV. However, the persistence of HIV-1 DNA as proviruses integrated into the human genome remains the main barrier to achieving a cure. Next-generation sequencing (NGS) offers increased sensitivity for characterising archived drug resistance mutations (DRMs) in HIV-1 DNA for improved treatment options. In this study, we present an ultra-sensitive targeted PCR assay coupled with NGS and a robust pipeline to characterise HIV-1 DNA DRMs from buffy coat samples. Our evaluation supports the use of this assay for Pan-HIV-1 analyses with reliable detection of DRMs across the HIV-1 Pol region. We propose this assay as a new valuable tool for monitoring archived HIV-1 drug resistance in virologically suppressed individuals, especially in clinical trials investigating novel therapeutic approaches.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHIV SeropositivityAnti-Retroviral AgentsDrug Resistance, ViralGenotypeHigh-Throughput Nucleotide SequencingHumansMutationAnti-HIV AgentsAnti-Retroviral Agentsdrug resistanceHIV-1HIV-1 DNANGSprovirussanger

Identifiers

PMID37766218
PMCPMC10536450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.